Japan’s health ministry approved a slew of new medicines on September 25 including multiple “first of its kind” products, among them being GlaxoSmithKline’s respiratory syncytial virus (RSV) vaccine Arexvy as well as Eisai’s Alzheimer’s therapy Leqembi (lecanemab).Arexvy became the first…
HOME > BUSINESS
BUSINESS
- Santen to Run Voluntary Redundancy Program Targeting Age 50 and Up
September 5, 2023
- Otsuka to Acquire Canada’s Psychedelic Specialist Mindset Pharma
September 4, 2023
- Enhertu Gets 2 More Breakthrough Therapy Tags in US: Daiichi Sankyo
September 4, 2023
- Shionogi Wins SCARDA R&D Funding for Nasal Vaccines for Flu, COVID
September 1, 2023
- Atozet Generic to Hit Japan Shelves on Sept. 1
September 1, 2023
- Ono, Twist Bio Tie Up on Antibody Discovery for Autoimmune Disorders
September 1, 2023
- 2 Amyloid PET Imaging Agents Expand Labels as Lecanemab Approval Nears
September 1, 2023
- Sobi’s PNH Drug to Hit Japan Market on Sept. 4, Taiho's FGFR Inhibitor on Sept. 7
August 31, 2023
- Novartis Rolls Out Luxturna in Japan, 2 Treatment Facilities Selected
August 31, 2023
- Sandoz Completes Acquisition of Astellas’ Antifungal Mycamine
August 31, 2023
- Toray to Kick Off Antibody PII Studies for Gastric Cancer
August 31, 2023
- Takeda Snags Japan Rights to ImmunoGen’s ADC
August 30, 2023
- Shionogi Rolls Out Flomox Fine Granules for Children in China
August 30, 2023
- First 10 Drugs Named for Medicare Price Negotiations, None from Japan Firms
August 30, 2023
- Oral Flu Drug Prescriptions 11 Times More than Pre-COVID: July Survey
August 29, 2023
- Nichi-Iko Winds Up Avastin Biosimilar Deal with Sandoz
August 29, 2023
- Pfizer Gets Breast, Ovarian Cancer Nod for Avastin Biosimilar
August 29, 2023
- Taiho Gets Options to French Firm’s GnT-V-Targeted Cancer Drug in Asia
August 28, 2023
- FDA Grants Priority Review for Xtandi in Earlier Type of Prostate Cancer
August 25, 2023
- Ayumi Walks Away from JPMA, Plans to Join JGA
August 23, 2023
ページ
“Time is the scarcest resource, and unless it is managed, nothing else can be managed.” - Peter DruckerSearching for the right candidate takes time… but how much time?The last thing you want is to waste time searching for the wrong…
A doctor member of the Central Social Insurance Medical Council (Chuikyo) on September 20 traded barbs with pharma leaders over…
The Ministry of Health, Labor and Welfare (MHLW) on September 19 proposed restructuring the Japanese generic industry by restricting the…
The Ministry of Health, Labor and Welfare (MHLW) plans to no longer require the implementation of additional PI clinical studies…
In the run-up to FY2024 budget requests this summer, there were growing hopes in the pharmaceutical industry that the government's de-facto cap on increases in social security spending would finally be lifted. That did not happen, despite strong calls from…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…